Treatment Guidelines: Neurocognitive Disorders

American Academy of Neurology (AAN)

• Aducanumab Use in Symptomatic Alzheimer Disease Evidence In Focus (2023)

American Psychiatric Association (APA)

• Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias (guideline watch, 2014)
• Practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia (2016)

American Psychological Association

• APA Guidelines for the Evaluation of Dementia and Age-Related Cognitive Change (2023)

British Association for Psychopharmacology (BAP)

• Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology (2017)

Deprescribing Guidelines in the Elderly Project

• Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia (2018)
• Evidence-based clinical practice guidelines for deprescribing cholinesterase inhibitors and memantine: recommendations (2018)

Indian Psychiatric Society (IPS)

• Clinical Practice Guidelines for Management of Dementia (2018)

National Institute for Health and Care Excellence (NICE)

• Dementia: assessment, management and support for people living with dementia and their carers (2018)

World Federation of Societies of Biological Psychiatry (WFSBP)

• Guidelines for the biological treatment of Alzheimer’s disease and other dementias (2011)

World Health Organization (WHO)

• Risk Reduction of Cognitive Decline and Dementia (2019)

Reviewer 1: Thea Moore, PharmD, BCPP
Reviewer 2: Austin Smith, PharmD, BCPP
2024-2025 AAPP Resident and New Practitioner Committee